Developing a Differentiated Gene Therapy for Sickle Cell Disease: Key Considerations

Time: 9:00 am
day: Day Two


  • Aligning with regulatory requirements for quality of gene therapies, across CMC & clinical development
  • Standing out from both a safety and efficacy perspective
  • Developing therapies in a ‘crowded’ market – with respect to gene therapies in development and existing standards of care